Introduction
Hashimoto's encephalopathy (HE), a rare but treatable disease, has a prevalence of only 2.1 cases per 100,000 persons 1 ; this along with the variability in presentation makes it a very challenging diagnosis. The following case report illustrates the responsiveness of this disease in a severely afflicted patient who failed to respond to steroids but had a prompt and complete response to plasmapheresis. We then review the literature regarding the diagnosis and treatment of HE.
Case report
A 45-year-old male found wandering outside his apartment building at night in freezing temperature wearing only his underwear was brought to the hospital by ambulance and appeared confused. The patient's family later confirmed that for one week prior, he had severe headaches, nausea and vomiting, slurred speech, and confusion. About 15 months previously, he had presented to another hospital with new onset seizures, was encephalopathic and was found to be hypothyroid. Extensive work-up had ruled out infectious, toxic, metabolic, malignant and paraneoplastic etiologies and Creutzfeldt-Jakob disease. His thyroid-stimulating hormone (TSH) levels ranged from 4.56 to 8.08 IU/ml. Anti-thyroid peroxidase antibodies (TPOAb) and antithyroglobin antibodies (TgAb) were markedly elevated (TPOAb >1000 IU/ml with normal levels <35 IU/ml, TgAb >3000 IU/ml with normal levels <20 IU/ml).
Initial treatment at the outside hospital with a combination of two anticonvulsants was ineffective. However, after 3 days of prednisone (60 mg/d) his seizures resolved. Unfortunately, attempts to taper steroids resulted in recurrent seizures despite concurrent treatment with levetiracetam and topiramate. Repeatedly, after increasing the prednisone to 60 mg/d, he would quickly improve with resolution of the seizures and delirium. He was finally tapered off steroids 6 months later and continued to function well, working daily, and had no seizure activity on mycophenolate mofetil, levetiracetam, topiramate and levothyroxine for about 9 months until this admission.
At our hospital, he was started on broad-spectrum antibiotics for possible infectious meningitis or encephalitis. Lumbar puncture revealed elevated CSF protein levels (221 mg/dl) without pleocytosis. His records from the hospital where he had been treated for HE's disease were reviewed and methylprednisolone was initiated at 60 mg/d IV every 12 h for 2 doses then every 8 h on the second and third days. Despite steroids, the patient's condition deteriorated with worsening disorientation, intermittent severe agitation, high fevers, and a persistent leukocytosis. CSF cultures were negative for common bacteria, acid-fast bacilli, fungi, cryptococcus antigen, herpes DNA polymerase chain reaction (PCR) and anti-neuronal nuclear antibody type 1. Blood and urine cultures were negative and toxicology screening was unrevealing. His TSH was 32.5 IU/ml, TPOAb and TgAb levels were >6500 IU/ml (normally <60 IU/ml) and >25,000 IU/ml (normally <60 IU/ml) respectively. Electroencephalogram (EEG) showed diffuse slowing and disorganiza- Hashimoto's encephalopathy is an under-recognized and rare disease that presents a diagnostic conundrum since many features are suggestive of infectious etiologies and yet treatment is immunosuppressive medications. We describe a case of a male with a history of recurrent seizures who presented with a subacute onset of confusion, persistent leukocytosis and fever while on immunosuppressant therapy, whose response to high dose steroids was incomplete and who achieved a complete remission of all symptoms when plasmapheresis was initiated. A negative cerebrospinal fluid (CSF) and serum microbiological testing in a patient with an abnormal EEG, increased CSF protein, and elevated thyroid antibodies should prompt consideration of Hashimoto's encephalopathy. If after treating with high dose steroids, there is a sub-optimal clinical response, plasmapheresis should be considered.
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tion of background activity without seizure activity. Magnetic resonance imaging (MRI) revealed non-enhancing bilateral hemispheric white matter T2/FLAIR hyperintensity. Methylprednisolone was then increased to 1 g/d IV for 5 days, and the patient exhibited a partial response with less agitation and improved orientation, but still was not close to baseline. Plasmapheresis was begun with a return to a normal mental status within the first 24 h. A total of 5 sessions were given and he was discharged home on prednisone (50 mg daily), levothyroxine, levetiracetam and topiramate. Gradually, he was tapered off prednisone and is symptom-free for over one year of follow-up on mycophenolate mofetil, levetiracetam, topiramate and levothyroxine.
Discussion
Since HE was first described by Brain et [4] [5] [6] [7] HE may present with unexplained episodes of relapsing myoclonus, generalized seizures, focal neurological deficits or psychiatric disorders and should have at least three of the following conditions: an abnormal EEG, elevated thyroid antibodies, elevated CSF protein and/or oligoclonal bands, an excellent response to steroids and a nonspecific but abnormal cerebral MRI. 8 The differential diagnosis includes viral encephalitis, CreutzfeldtJakob disease, central nervous system vasculitis, and paraneoplastic autoimmune encephalopathies.
HE is also known as ''steroid-responsive encephalopathy associated with thyroid autoimmunity''. It is different from neurologic complications of hypothyroidism in that the addition of thyroxine will not cure the patient and the disease will demonstrate progression of neurologic symptoms without significant immunosuppressive therapy.
The pathogenesis of HE remains unclear. Autoimmune vasculitis is purported to play a role and evidence for this is perivascular lymphocytic infiltration seen in five of seven of the pathology reports from brain tissue samples. 3, 9 Other hypotheses are that the cerebrospinal fluid thyroid autoantibodies, either synthesized intrathecally or systemically derived and crossing the damaged blood-brain barrier, may react with a putative intracranial antigen and form localized immune complexes. [10] [11] [12] The improvement of the symptoms with steroids or plasmapheresis is indirect evidence of the role of auto-immunopathology. [13] [14] [15] [16] Elevated titers of anti-thyroid antibodies (especially TPOAb) are considered to be a hallmark of HE. Some authors contend that antibody levels have little causality and have found no relationship to disease severity, 3, 17 as was true in our case. This patient's TPOAb and TgAb levels did not change and remained high even when he was symptom-free (TPOAb >1000 IU/ml with normal levels <35 IU/ml, TgAb >3000 IU/ml with normal levels <20 IU/ml 10 months after he first presented). However, with these persistently high levels, he did relapse 15 months later. This also has been found to be the case where patients with fluctuation in their symptoms had either persistently high or highly variable levels of antithyroid antibodies. Similarly, patients who failed to respond to steroids also more often had persistent elevation in antithyroid antibodies 13, 15, 18 ; thus, normalization of the serum antithyroid antibodies normalize may be a good prognostic sign with a higher chance of successful weaning of steroids and remaining symptomfree with treatment. 4, [13] [14] [15] [16] 18 In summary, although persistent elevated anti-TPOAb levels do not correlate with disease severity, it seems that they do appear to be predictive of relapses, a prolonged disease course, less responsive to steroids, and a worse prognosis. The authors suggested that serial antithyroid antibody levels could be used both to predict the disease course as well as response to therapy. Patients with high anti-TPOAb levels often require a very slow steroid tapering, and consideration should be given to combining steroids with other immunosuppressive agents to avoid recurrence of HE. 18 Treatment of HE consists of immunosuppressive agents and/or thyroid hormone replacement, as well as anticonvulsant drugs for seizures. Initial treatment usually is prednisone, which is tapered within weeks to months according to clinical response. Even with maintenance steroids or immunosuppressant therapy, relapses are not rare. With recurrence of HE, an increased steroid dose or pulse dosing may be needed, 15, 18 and patients may evolve with time to a steroid-resistant state. Given the immunosuppression of these patients, the exclusion of an infectious cause is critically important.
Immune modulation with serial plasmapheresis may be a more effective strategy than additional immunosuppression in those who have relapsed or who have shown steroid resistance with significant improvement usually seen after the first treatment. 13, 14, 19 Over time, the course of this disease is generally either remitting-replasing with acute/subacute seizures or stroke-like episodes, or is progressive with an insidious onset of dementia or psychosis that steadily worsens. 15, 18, 20 The remitting-relapsing type is reported to be more common in younger patients as our patient, and it has been shown that these patients respond well to steroids and have a better prognosis. On the other hand, the progressive type is seen more commonly in older patients, and clinical findings resemble those seen in Creutzfeldt-Jakob disease, and it is more likely to be partially or poorly responsive to steroids. The latter presentation clinically must be ruled out for CreutzfeldtJakob disease. This patient's complete and rapid response to plasmapheresis was dramatic. The exclusion of infection especially given the fever on presentation, the review of outside records showing a history of HE, the early trial of high dose of steroids (e.g., methylprednisonlone 1 g/d for 3-5 days), and lastly the addition of plasmapheresis yielded dramatic improvement. The rapidity which this was done also shortened his hospitalization and minimized nosocomial complications. Including HE in the differential diagnosis of patients with acute encephalopathy is important since this rare illness is often fully reversible with appropriate therapy that includes steroids and plasmapheresis.
